References
- Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26:335–346.
- Goswami T, Jasti BR, Li X. Sublingual drug delivery. Crit Rev Ther Drug Carrier Syst. 2008;25:449–484.
- Chaves PS, Frank LA, Ourique AF, et al. Carvedilol-loaded nanocapsules: mucoadhesive properties and permeability across sublingual mucosa. Eur J Pharm Biopharm. 2017;114:88–95.
- Volpe DA. Application of method suitability for drug permeability classification. Aaps J. 2010;12:670–678.
- Teubl BJ, Meindl C, Eitzlmayr A, et al. In-vitro permeability of neutral polystyrene particles via buccal mucosa . Small. 2013;9:457–466.
- Wang Y, Zuo Z, Lee KK, et al. Evaluation of HO-1-u-1 cell line as an in vitro model for sublingual drug delivery involving passive diffusion—Initial validation studies. Int J Pharm. 2007;334:27–34.
- Murdoch C, Reeves KJ, Hearnden V, et al. Internalization and biodistribution of polymersomes into oral squamous cell carcinoma cells in vitro and in vivo. Nanomedicine (Lond). 2010;5:1025–1036.
- Nibha KP, Pancholi SS. An overview on: sublingual route for systemic drug delivery. Int J Res Pharmaceut Biomed Sci. 2012;3:913–923.
- Teubl BJ, Absenger M, Fröhlich E, et al. The oral cavity as a biological barrier system: design of an advanced buccal in vitro permeability model. Eur J Pharm Biopharm. 2013;84:386–393.
- Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–1116.